Malaria is one of the most devastating diseases in the world, affecting almost 225 million people a year, and causing over 780,000 deaths, most of which are children under the age of 5 years. Following the recent call for the eradication of the disease, supported by the WHO, there has been increasing investment into antimalarial drug-discovery projects. These activities are aimed at generating the next generation of molecules focused on the treatment and transmission-blocking of Plasmodium falciparum and P. vivax endo- and exo-erythrocytic stages of the parasite. This article summarizes the current top-level thinking regarding the prosecution of such endeavors and the disease-specific considerations in project planning.
Burrows, J.N.; Leroy, D.; Lotharius, J.; Waterson, D. Challenges in antimalarial drug discovery. Future Medicinal Chemistry (2011) 3 (11) 1401-1412. [DOI: 10.4155/fmc.11.91]